Nautilus Biotechnology (NAUT) Set to Release Earnings on Tuesday

Key Points

• Nautilus Biotechnology is expected to report Q3 2026 results before the market opens on October 27. Analysts forecast a loss of $0.14 per share and revenue of approximately $0.21 million.
• The company exceeded expectations in the previous quarter, reporting a $0.11 per-share loss versus the $0.14 expected loss, while revenue reached $0.19 million compared with the $0.10 million consensus estimate.
• NAUT shares have risen 27.7%, and analyst sentiment is moderately bullish, with a consensus price target of $3.83 versus the stock’s recent $2.63 price. Ratings include one Strong Buy, two Buys, one Hold, and one Sell.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $0.21 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last announced its quarterly earnings data on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.10 million. On average, analysts expect Nautilus Biotechnology to post ($0.52) EPS for the current fiscal year and ($0.53) EPS for the next fiscal year.

Nautilus Biotechnology Stock Up 27.7%

NASDAQ:NAUT opened at $2.63 on Tuesday. The business's 50 day moving average is $1.24 and its two-hundred day moving average is $1.91. Nautilus Biotechnology has a 52 week low of $0.84 and a 52 week high of $4.31. The company has a market cap of $334.67 million, a PE ratio of -5.84 and a beta of 0.73.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on NAUT shares. Weiss Ratings downgraded Nautilus Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, August 5th. Leerink Partners initiated coverage on Nautilus Biotechnology in a research report on Wednesday, September 9th. They set an "outperform" rating and a $4.00 price target on the stock. Roth Capital started coverage on Nautilus Biotechnology in a research note on Tuesday, September 29th. They set a "buy" rating and a $3.50 price objective on the stock. Finally, Zacks Research raised shares of Nautilus Biotechnology to a "hold" rating in a report on Wednesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $3.83.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to enable more comprehensive, sensitive and efficient study of the proteome, the full set of proteins expressed by a biological system, to support research in drug discovery, disease biology and translational science.

The company's primary offering is the Nautilus Proteome Analysis Platform, which combines a proprietary analytical instrument, consumables and software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.